Avant Technologies Completes Rebranding with Name Change to Avaí Bio and Launch of New Website
MWN-AI** Summary
Avant Technologies, Inc., a biotechnology company specializing in cell-based therapies, has officially rebranded to Avaí Bio, Inc. The change, announced on February 11, 2026, is part of the company's evolution to emphasize its commitment to developing innovative treatments for diabetes and age-related disorders. The new name, Avaí Bio, reflects a focused mission to deliver groundbreaking therapies for type 1 diabetes and insulin-dependent type 2 diabetes, as well as to promote healthy longevity.
Trading under the ticker symbol AVAI on OTC Markets, the company has also launched a revamped website that provides comprehensive information about its new corporate identity and innovative pipeline. CEO Chris Winter highlighted that this rebranding signals a shift from a technology-centric focus to a dedicated pursuit of cellular medicine solutions.
Avaí Bio's strategic direction includes advanced programs such as the Diabetes Development Program, which aims to create genetically modified cell lines capable of producing, storing, and secreting insulin—alongside proprietary encapsulation technologies to prevent immune rejection. Additionally, the company is advancing its Klotho Development Program, targeting the "longevity protein" to address age-related decline and chronic diseases.
Through strategic collaborations like Insulinova and Klothonova, Avaí Bio aims to accelerate clinical translations of their research efforts, forming alliances that enhance their research and development capabilities. The rebranding to Avaí Bio not only aligns with its innovative pipeline but also positions the company to attract valuable partnerships, ultimately enhancing its ability to deliver life-changing therapies to patients in need. More information can be found on their newly launched website, www.avaibio.com.
MWN-AI** Analysis
Avaí Bio, formerly Avant Technologies, has undertaken a significant rebranding effort that should not go unnoticed by investors looking for opportunities in the biotech sector. This move aligns with the company’s renewed focus on developing cell-based therapies, particularly for diabetes and age-related disorders—conditions with substantial unmet medical needs and market potential.
With the name change to Avaí Bio, the company aims to better communicate its mission to innovate cellular medicine. This clarity could enhance its visibility to potential partners and investors, making it an appealing candidate for strategic collaborations. The distinctive focus on genetically modified cell lines and advanced encapsulation technologies signifies a shift towards cutting-edge treatments, which may attract institutional investment.
The development programs announced—specifically targeting diabetes and anti-aging—are particularly noteworthy. The emphasis on creating immunoprotective, insulin-producing cell lines could position Avaí Bio as a leader in diabetes treatment options. Given that diabetes affects millions globally, the market for such therapies is enormous. Similarly, the exploration of the longevity protein, ?-Klotho, further expands its reach into the burgeoning anti-aging sector.
Investors should also keep an eye on Avaí Bio's strategic collaborations, exemplified by Insulinova and Klothonova. Successful execution of these partnerships could expedite clinical trials and enhance market readiness for their pipeline products.
However, potential investors should proceed cautiously, as the biotech sector is inherently volatile, and the company's future performance may hinge on regulatory approvals and market adoption. Following Avaí Bio's updates and sector trends will be crucial in gauging the viability of investment decisions in this transformative period for the company.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
LAS VEGAS, Feb. 11, 2026 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company focused on developing cell-based therapies for diabetes and age-related disorders, today announced the completion of its corporate name change to Avaí Bio, Inc. (OTCQB:AVAI). The rebranding, effective today, February 11, 2026, reflects the Company's sharpened focus on advancing transformative treatments for type 1 and insulin-dependent type 2 diabetes, age-related diseases, and healthy longevity through genetically modified cellular platforms and protective encapsulation technologies.
The Company's common stock will continue trading under the ticker symbol AVAI on OTC Markets, with no change to the CUSIP number. Shareholders, partners, and investors can now access the updated corporate identity and comprehensive pipeline details at the new website: https://www.avaibio.com.
"This name change marks a defining moment in our evolution from a technology-focused entity to a dedicated biotechnology innovator at the forefront of cellular medicine," said Chris Winter, CEO of Avaí Bio. "Avaí Bio better captures our mission to deliver life-changing therapies that address unmet needs in diabetes management, age-related diseases, and anti-aging. By leveraging genetically engineered cell lines, state-of-the-art encapsulation to shield cells from immune rejection, and strategic joint ventures, we are positioned to accelerate progress toward functional cures and extended healthy lifespans."
Key elements of Avaí Bio's pipeline include:
Diabetes Development Program: Genetically modified cell lines engineered to produce, store, and secrete insulin, combined with proprietary encapsulation for immune protection—aiming to provide a sustainable, immunosuppression-free solution for type 1 and insulin-dependent type 2 diabetes.
?-Klotho Development Program: Advancement of a "longevity protein" overexpression cell line to combat age-related decline, targeting broader anti-aging and chronic disease applications.
Strategic collaborations, including the formation of Insulinova (diabetes program) and Klothonova (?-Klotho program) to drive clinical translation through joint research, licensing, and encapsulation expertise.
By rebranding to Avaí Bio, the Company aligns its corporate identity with its core operations in sourcing, developing, and protecting advanced cellular therapies—positioning it to attract top-tier partnerships, accelerate R&D, and bring groundbreaking treatments closer to patients.
About Avaí Bio, Inc.
Avaí Bio, Inc. is an emerging biotechnology company focused on identifying genetically modified cell lines, and through joint venture and licensing agreements developing innovative cell-based therapies.
More information about Avaí Bio can be found at https://www.avaibio.com
You can also follow us on social media at:
https://x.com/AvaiBio
https://www.facebook.com/AvaiBio
Forward-Looking Statements
Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.
Contact:
Avaí Bio, Inc.
info@avaibio.com
Logo: https://mma.prnewswire.com/media/2902043/Avai_Bio_Logo.jpg
SOURCE AVAI Bio Inc.
FAQ**
How does the rebranding from Avant Technologies Inc. AVAI to Avaí Bio align with the company's mission in developing cell-based therapies for diabetes and age-related disorders?
What strategic collaborations and joint ventures has Avaí Bio, formerly Avant Technologies Inc. AVAI, planned to accelerate R&D and clinical translation of their diabetes and longevity programs?
Can Avaí Bio, previously known as Avant Technologies Inc. AVAI, provide more details on the proprietary encapsulation technologies being used to protect genetically modified cell lines from immune rejection?
How does the launch of Avaí Bio’s new website aim to enhance communication with shareholders and investors compared to the previous platform associated with Avant Technologies Inc. AVAI?
**MWN-AI FAQ is based on asking OpenAI questions about Avant Technologies Inc. (OTC: AVAI).
NASDAQ: AVAI
AVAI Trading
-5.03% G/L:
$0.34 Last:
18,124 Volume:
$0.35 Open:
